Image Box 1st to successfully position ISCT comment on Novartis' CAR-T FDA approval.
Image Box and ISCT identified the FDA approval of the Novartis CAR-T as a significant opportunity for ISCT to comment, further increasing its visibility and positioning as the cell therapy market leading organisation. Image Box worked with ISCT leaders to draft a press release for the market prior to the approval. It contained specific key messages of specific interest to international media organisations with academic, industry and regulatory readership. The release was distributed by Image Box within minutes of confirmation from ISCT that the approval had been released by the FDA. This was confirmed by journalists that ISCT’s comments on the FDA Novartis CAR-T approval were by far the first to hit the market.
Image Box discussed the ISCT release with a variety of international media, and arranged interviews with journalists from key publications from the Wall Street Journal (US) to top life science publications such as BioWorld, The Pink Sheet, Scrip Intelligence, BioWorld, BioPharm Insight, APM Health Europe, BioPharma Reporter, MedNous, and other leading publications.